Zenotech Laboratories Limited (ZENOTECH) Fair Value & Analysis
Healthcare · IN · Market cap ₹2.8B
Fair value as of: Jul 6, 2026
From 13 valuation models · updated today
Share price +3.5% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹34.29 – ₹62.45 · fair‑value band ₹7.70 – ₹8.64 · the ₹45.95 price screens above the ₹8.19 fair value. As of Jul 6, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Zenotech Laboratories Limited (ZENOTECH) currently trades at ₹45.95, while our model-based Fair Value estimate is ₹8.19 — implying the stock looks roughly 82.2% overvalued today. We read business quality at 53/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Zenotech Laboratories Limited generated revenue of ₹396M at a net margin of -2.7%. Revenue declined 21.1% year over year. It earns a return on equity of -1.1%. Net debt stands at ₹35.9M. Fundamentals as of Jul 6, 2026
Our scenario range runs from ₹7.70 (bear case) to ₹8.64 (bull case); at ₹45.95, the current price sits above that range. The share trades about 28% below its 52-week high and 37% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside — at -82%, ZENOTECH screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 6, 2026. TTM = trailing twelve months.
About the company
Zenotech Laboratories Limited manufactures and markets pharmaceutical specialty generic injectables in the oncology and anesthesiology markets in India. The company offers contract manufacturing services for parenteral depot formulations, ophthalmic, oncology oral and injectables, and general injectables; and leases its biotech facility and equipment. It also provides biotechnology products, such as granulocyte-colony stimulating factors and granulocyte-macrophage colony-stimulating factors. Zenotech Laboratories Limited was incorporated in 1989 and is based in Hyderabad, India.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Zenotech Laboratories Limited reported revenue of ₹396M in FY2025 versus ₹366M in FY2021, a compound +2.0%/yr. Reported net income was −₹10.7M in FY2025.
Is ZENOTECH fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,464 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,377 | ₹628.39 | -54% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,291 | ₹1,053 | -18% |
| PharmaEssentia Corporation 6446 | 934.00 TWD | 365.87 TWD | -61% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Zenotech Laboratories Limited (ZENOTECH) undervalued?
What is the fair value of ZENOTECH?
What is the quality score of ZENOTECH?
What is the revenue of Zenotech Laboratories Limited (ZENOTECH)?
What is the net profit margin of ZENOTECH?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.